AIPPI: Personalised medicine tests the limits in patent law
At AIPPI’s World Congress 2025, a panel explored how personalised medicine is pushing patent law into new territory, and why harmonisation remains a distant goal.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
22 June 2026 The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.
27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.